Dr. Alfred Jost pioneered the field of reproductive endocrinology with his seminal observation that two hormones produced by the testes are required for the male embryo to develop a normal internal reproductive tract. T induces the Wolffian ducts to differentiate into epididymides, vasa deferens, and seminal vesicles. Mü llerian inhibiting substance (MIS) causes regression of the Mü llerian ducts, which in its absence would normally develop into the Fallopian tubes, uterus, and upper vagina as is observed in female embryos. This review will summarize our current understanding of molecular mechanisms underlying the function of MIS both as a fetal gonadal hormone that causes Mü llerian duct regression and as an adult hormone, the roles for which are currently being investigated, i.e., inhibition of steroidogenesis, germ cell development, and cancer. We will also address the regulation of MIS expression as one of the first genes expressed after the commitment of the bipotential gonads to differentiate into testes under the influence of SRY, the gene on the sex-determining region of the Y chromosome. We will discuss what is known regarding MIS signal transduction, which as with other members of the TGF␤ family of growth and differentiation factors, occurs through a heteromeric complex of single transmembrane serine/threonine kinase receptors to effect downstream signaling events, including Smad, nuclear factor-B, ␤-catenin, and p16 activation. Finally, we will assess the clinical relevance of studying MIS in patients with persistent Mü llerian duct syndrome and our efforts to determine the therapeutic value of MIS for patients with ovarian andotherMISreceptor-expressingcancers. (EndocrineReviews  22: 657-674, 2001) 
M Ü LLERIAN INHIBITING SUBSTANCE (MIS, also
known as anti-Mü llerian hormone or AMH) has long been known for its signature developmental effect of causing regression of the Mü llerian ducts, the anlagen of the uteri, Fallopian tubes, and upper vagina in mammalian species, a requirement for normal male reproductive tract development ( Fig. 1) . T, another hormone produced by the fetal testis, is required for Wolffian duct differentiation into the male internal reproductive tract structures. MIS-mediated regression of the Mü llerian duct is a classic example of tissue resorption, which, if understood and harnessed, could be instructive in how to control the growth of Mü llerian ductderived tumors, particularly those that bind the ligand. Efforts to uncover the molecular mechanisms of MIS-mediated Mü llerian duct regression by several laboratories over the last few decades and previously reviewed in Refs. 1-4 have brought the study of MIS from phenomenology as a biological curiosity into the molecular era. The genes encoding MIS and its receptors have been cloned, and the signal transduction pathways that are used by MIS are being investigated to understand more fully its role in fetal and adult gonads, extragonadal tissues, and in deregulated tissues including cancers. The sexually dimorphic regulation of MIS expression is also a fruitful area of inquiry since it is an early marker in mammals for the genetic switch that occurs when a bipotential gonad is instructed to differentiate into a testis in response to the testis-determining factor, SRY (sex-determining region of the Y chromosome) (5, 6).
Understanding the mechanisms of action of MIS, which is a member of the larger TGF␤ family of growth and differentiation factors, helps to elucidate the molecular pathways leading to growth inhibition and differentiation in MISresponsive cells. The general pathways used by members of the TGF␤ family appear to be common or interchangeable for the great variety of physiological responses elicited, but ligand-and/or cell-specific molecular control mechanisms can use these signal transduction pathways in unique combinatorial ways to elicit ligand-and tissue-specific responses. In this regard, MIS has further appeal both because of its sexual dimorphism and relative specificity and, whereas other TGF␤ family members may have more ubiquitous effects, MIS may be more targeted. MIS is a model system in which common basic molecular mechanisms employed by highly targeted growth inhibitors can be elucidated for translational applications in the treatment of disease processes. Therein lies its intellectual and practical appeal.
II. The MIS Ligand and Its Biological Effects

A. History of the discovery of MIS
The German anatomist and physiologist, Johannes Mü ller (1801-1858) is credited with the first description of what later became known as the Mü llerian ducts, the anlagen of the uterus, Fallopian tubes, and upper vagina. The Wolffian ducts, named for the German anatomist Caspar F. Wolff (1733-1794), are the male counterparts of the Mü llerian ducts and differentiate into the vasa deferens, epididymides, and seminal vesicles. A half-century later, Lillie (7) reported the freemartin calf, the product of heterosexual twins with a shared placenta. This phenomenon, which was also recognized as an early example of immunological chimerism, became equally important to the understanding of reproductive biology, since the female of the twin pair showed regression of the Mü llerian ducts and was masculinized externally, presumably due to soluble factors produced by the male gonads of the anastomosing male twin, which we now know to be MIS and T.
Alfred Jost (8) performed seminal in vivo embryonic experiments that demonstrated the existence of what he called the Mü llerian "l'hormone inhibitrice" or the "Mü llerian inhibitor." Using embryonic testicular fragments implanted in embryonic female rabbits before the time of sexual differentiation, he found, like the freemartin calf, that the animals were virilized externally and showed stimulation of Wolffian ducts and regression of the Mü llerian ducts. When he replaced the testes with T pellets, the female embryos became masculinized, but did not show regression of the Mü llerian ducts. These experiments caused him to propose the existence of another testicular product (9) in addition to T, which we now call Mü llerian inhibiting substance (MIS). These observations allowed him to explain the phenotypic differences between patients with intersex abnormalities due to congenital adrenal hyperplasia, in which excess adrenal T masculinized the external genitalia of a female, but did not affect the normal Mü llerian ducts, and androgen insensitivity syndromes, then referred to as testicular feminization, in which the testes continued to produce functional MIS, causing normal regression of the Mü llerian duct (10).
In the absence of research funding after World War II in France, Jost used rabbits indigenous to the Bois de Boulogne to perform his experiments. They were hardy animals that withstood manipulation in utero. The New Zealand White rabbits later developed for research purposes were more susceptible to spontaneous abortion; hence, Jost's experiments proved difficult to repeat. Thankfully, they were later recapitulated in vitro when Picon (11) in Jost's laboratory developed an organ culture assay using rat embryonic agonadal urogenital ridges, which showed regression of the Mü llerian duct when cocultured with fetal testes.
B. Mü llerian duct regression
In the late 1950s the concept of programmed cell death was introduced, and Hamilton and Teng (12) later described the FIG. 1. Differentiation of the reproductive tract. In mammals with XY chromosomes, the bipotential gonad differentiates into a testis under the influence of SRY, the testis-determining factor on the Y chromosome. The testes produce T, required for differentiation of the Wolffian duct into the epididymides, vas deferens, and seminal vesicles, and MIS, required for the regression of the Mü llerian duct. In the absence of a Y chromosome and SRY, the indifferent gonad will differentiate into an ovary. Without T, the Wolffian duct degenerates, and without MIS, the Mü llerian duct differentiates into the upper vagina, uterus, and Fallopian tubes.
regression of the Mü llerian duct as a classic example of apoptosis in tissue remodeling during organogenesis. This process, also observed during resorption of the interdigital spaces in the formation of the digits (13, 14) and with branching morphogenesis of the salivary gland and the lung (15), was characterized by the formation of dense intracellular particles rich in lysosomal enzymes, which preceded phagocytosis by adjacent cells. Electron microscopy of the regressing male Mü llerian ducts clearly visualized the autophagocytotic process (16); similar observations were made on Mü llerian ducts in vitro under the influence of cocultured testicular fragments (17). Further analysis using electron microscopy and markers for membrane-specific proteins demonstrated breakdown of the basement membrane as one of the earliest morphological signs of Mü llerian duct regression (18, 19). The fragmentation was accompanied by loss of fibronectin staining (20) and detachment of the epithelial cells, which were observed to migrate out of the epithelial compartment to contribute to a mesenchymal cuff around the disrupted basement membrane (18, 21). Some of the cells undergoing epithelial-mesenchymal transformation migrated deep into the mesenchyme (18, 22). When studied in chick-quail chimeras (23), these migrating cells were observed to take up residence progressively in the mesonephros, which is itself subsequently resorbed.
That there must be cross-talk between the mesenchymal and epithelial layers for Mü llerian duct regression to occur was recognized early (24, 25), an observation strengthened by the expression of the MIS receptor components in the mesenchyme surrounding the duct (see Sections III.B and III.C). More recent analyses of internucleosomal DNA fragmentation, a hallmark of the apoptotic process, have confirmed that MIS can induce apoptosis in the Mü llerian duct epithelial cells (26) via a paracrine mechanism from signals derived from the MIS type II receptor-expressing mesenchyme (27) and that the apoptosis is progressive from the cranial to caudal direction and might involve ␤-catenin (22). It has been appreciated for some time that the cranial or cephalic part of the Mü llerian duct, which becomes the Fallopian tube, was more sensitive to MIS (22, 28). The histology of this Mü llerian domain characterizes the most common human ovarian cancers, the cystadenocarcinomas, which are often referred to as Mü llerian tumors (29).
C. Cloning, expression, purification, and cleavage of MIS
Evidence that the Sertoli cells produce MIS was first shown by Josso (30) , who separated seminiferous tubules from interstitial cells and cultured each separately with the agonadal urogenital ridge from 14-d-old rat fetuses and found that the Mü llerian duct regressed under the influence of only the seminiferous tubules, even when depleted of germ cells (31). The Sertoli cell factor was found to be heat sensitive and thus was likely a protein (30, 32). Rat testes continued to produce enough MIS after birth to cause some regression of the Mü llerian duct, but the levels fell precipitously by 3 wk (33), whereas calf testes continued production for 8 -10 postnatal weeks (34). Therefore, both fetal and newborn calf testes were used as a source for purification of MIS (34, 35). Various extraction techniques of testes fragments, followed by dialysis, ammonium sulfate precipitation, and ion exchange chromatography, were used to purify biologically active fractions (36) that were further purified by carbohydrate and dye affinity chromatography (37, 38). Homogeneous fractions of MIS were first purified using a combination of ammonium sulfate precipitation, ion exchange chromatography, and iterative immunoaffinity chromatography that resulted in a single major band at 72 kDa (39).
N-terminal and internal sequencing yielded amino acid sequences that were used to design degenerate oligonucleotide probes to screen a cDNA library constructed from newborn calf testes (40) from which the protein itself had been originally purified (38). A full-length bovine MIS cDNA was cloned and used as a probe to clone human genomic MIS and two overlapping human cDNAs, which covered the predicted full-length human cDNA. Similarly, overlapping cDNAs were also cloned from a bovine fetal testis library (41). Transfection of human genomic MIS in Chinese hamster ovary (CHO) cells resulted in expression and secretion of the full-length human MIS protein (40), which was functional in the organ culture assay of Mü llerian duct regression and in antiproliferative assays. The MIS gene and/or cDNA has also been cloned in other species including rat (42), mouse (43), chicken (44, 45), and alligator (46). The overall homology between the human sequence and the other species range from 27% and 33% identity for chicken and alligator to between 74% and 68% for bovine, rat, and mouse.
Monoclonal and polyclonal antibodies were raised to the MIS protein and used effectively for Western blot analysis, immunohistochemistry, and for the design of a specific and sensitive MIS ELISA (47-49). These monoclonal antibodies were also used to purify MIS from serum-containing media of CHO cells transfected with the MIS gene (50). Recombinant human MIS (rhMIS), purified by immunoaffinity chromatography (50) and found to cause regression of the Mü llerian duct, was used in antiproliferation assays where it inhibited growth of Mü llerian tumors in vitro (51) as well as growth and metastases of an ocular melanoma cell line in vitro and in vivo (52-54). Holo-MIS was cleaved into its Nand C-terminal domains by treatment with plasmin (55). The C-terminal domain was purified and found to be the biologically active moiety after cleavage at position 427/428 at a kex-like cleavage site characterized by R Ϫ4 XXR Ϫ1 with a serine in the ϩ1 site, which makes the MIS cleavage site monobasic (56). Addition of the N terminus was shown to enhance the biological activity of the C-terminal moiety (57), an unusual result for the TGF␤ family. Because its expression has been correlated with MIS and it can efficiently cleave pro-MIS, PC5 has been suggested as the natural proprotein convertase for MIS (58).
More recently, we have employed fast performance liquid chromatography to purify human MIS to homogeneity from serum-free media of transfected CHO cells producing rhMIS. Using serum-free media as the starting material substantially reduces the number of proteins from which the rare MIS product must be separated. The resultant more homogeneous MIS preparation, which is produced at higher yield and is up to 10-fold more potent when tested in bioassays (58a) is being scaled up to conform to Food and Drug Administration requirements for preclinical in vivo testing against human ovarian tumor xenotransplants, before phase I clinical trials. After fast performance liquid chromatography separation of plasmin-treated holo-MIS from this preparation, the C terminus appears as a single band by gel electrophoresis and is suitable for crystallography (T. Stehle, P. K. Donahoe, and D. T. MacLaughlin, unpublished observations).
D. Diagnostic utility of MIS measurements: ELISA and bioassays
A mouse monoclonal antibody raised to recombinant human holo-MIS (48) recognized holo, but not the C-terminal domain of rhMIS. Purified holo-MIS protein was also used to raise rabbit polyclonal antibodies that, when combined with the monoclonal ␣MIS in a sandwich assay, were used to constitute an ELISA that was sensitive to 1 to 2 ng/ml. When normal humans were tested, MIS was found to be elevated constitutively in serum of prepubertal males. MIS levels were shown to drop for a short time immediately after birth, peak within 3-6 months, and were maintained throughout infancy and childhood. MIS then slowly decreased just before puberty when a fall in MIS preceded the onset of puberty (59, 60). The lower levels were subsequently maintained throughout male adult life in the 2-5 ng/ml range. The concentrations of postneonatal serum MIS and T are inversely related in males (see Fig. 2 ) (59 -62). Females, conversely, had undetectable serum levels by ELISA until the prepubertal period (47-49), although recent immunohistochemical evidence indicates that MIS might be expressed in granulosa cells of preantral follicles (63). After puberty, serum MIS levels of 2-5 ng/ml (ϳ10 pm) were maintained until menopause when MIS was no longer be detectable. Thus, in childhood, MIS can serve as a useful and reliable marker (60) for the presence of testicular tissue when levels of T are very low. In the adult, when MIS is produced both in the Sertoli cell in the male and the granulosa cells in the female, the assay could not differentiate between normal males and females (60).
We and others (64, 65) have found serum MIS to be very useful in the differential diagnosis of patients with intersex disorders and an instructive marker when evaluating androgen insensitivity/steroidogenic disorders (66), particularly in the infant or young male, in whom the normally low and fluctuating T levels cannot be detected unless stimulated with hCG or LH. Thus, constitutively elevated MIS levels can be very definitive in patients with ambiguous genitalia abnormalities. For example, MIS is absent in female patients with congenital adrenal hyperplasia, but very high in patients with male pseudohermaphroditism (64), despite indistinguishable appearance of the external genitalia, which are discordant with the chromosomal sex. Intermediate MIS levels can be found in patients with mixed gonadal dysgenesis, depending upon how much destruction of the gonad has occurred (67). The assay has been very helpful in following patients with true hermaphroditism after partial gonadectomy to assure the surgeon, endocrinologist, and parents that all testicular tissue has been removed (64).
MIS is particularly helpful in the patient with bilateral nonpalpable gonads (68). In patients with bilateral testicular torsion in utero, MIS levels will be undetectable; the external genitalia is masculine, but the gonads cannot be palpated due to torsion, which presumably occurred late in gestation after external virilization had taken place under the influence of previously normal testes. In cases of bilateral retractile testes, MIS levels would be normal. These gonads can often, but not always, be maneuvered into and palpated in the inguinal canal or scrotum; when this is not possible, normal MIS levels provide reassurance that testes (68) are present, as it is in patients with congenital hypogonadotropic hypogonadism (69), since ultrasound and magnetic resonance imaging may be less reliable at this age. It has not been possible to use the MIS ELISA to help in assessing the unilateral undescended testes since levels are not significantly different from normal.
MIS levels can be dramatically elevated in females with granulosa cell tumors (70 -73). The ELISA could be used to detect new and recurrent cases of juvenile granulosa cell tumors, which tend to be benign, or the often postmenopausal adult tumors that are highly malignant and for which the best therapy remains early surgical excision. These tumors are often unresponsive to radiotherapy; multiple chemotherapeutic agents are necessary to elicit a response, but subsequent to initial responses they can have a high recurrence and mortality rate. The assay is probably best used in detecting early recurrences, when rising MIS levels have been detected before such tumors can be seen by computerized tomography or magnetic resonance imaging. Hence, we and others have turned to MIS assays to help manage these patients with granulosa cell tumors (70 -72). Although elevated E can be helpful in the differential diagnosis of granulosa cell tumors, it is not informative when a normal ovary is still in place as is often the case in patients with juvenile granulosa cell tumors (74, 75).
E. Regulation of MIS expression
MIS is a critical component in the cascade of mammalian sex differentiation as an early gene product after the gonad differentiates into a testis under the influence of SRY (76), and its embryonic sexually dimorphic expression has been a useful marker in the identification of factors activating the molecular switch that causes the indifferent gonad to differentiate into a testis. MIS expression is conserved among mammalian species and is tightly regulated in a developmental and tissue-specific manner in fetal, neonatal, prepubertal, and adult Sertoli cells, as well as prepubertal and adult granulosa cells. Despite intense study, the factors that determine this complex MIS expression pattern are still not fully understood. Transcription factors and promoter elements that affect both basal and regulated MIS expression during the fetal and neonatal period (as reviewed by Ref. 6 ) and perhaps in some cases in the adult have been elucidated by a number of laboratories. Also, correlative data indicate that MIS expression might be regulated by androgens (66), gonadotropins (77, 78), and by meiotic germ cells (79). There is no direct evidence that MIS expression is regulated by estrogens. However, it has been observed that MIS mRNA abundance in the ovary is increased 2-fold in ER␣ and -␤ double knockout mice (ERKO␣␤) (80), but it may not be reflected at the protein level (81).
Transcription of eukaryotic genes is dependent upon regulatory elements in the enhancer and core promoter region; the latter is usually composed of consensus TATA and CCAAT box elements. Unlike the rodent MIS core promoters, the human MIS core promoter was studied (82) because it had no consensus TATA element. After deletion and mutational analyses, a region of the core promoter (Ϫ6 to ϩ10) found to be essential for basal transcription was identified as the human MIS initiator element, although consensus with other known initiator elements of, for example, the adenovirus major late (83) or V␤ genes (84), was not high. Transcription of the MIS gene from this region was found to require transcription factor, TFII-I (82), a TATA-associated factor that recognizes selected initiator elements.
The SAP62 gene is only 328 bp upstream of the start site for transcription of mouse MIS and only 762 bp upstream for that of human MIS (85). Hence, it is likely that the region conferring critical control of MIS expression is located relatively close to the transcriptional start site. Moreover, this proximal promoter displays a number of evolutionary conserved elements including those for steroidogenic factor 1 (SF-1), an orphan nuclear receptor critically important for development of the hypothalamic-pituitary-gonadal and adrenal axes (86, 87); GATA-4, a zinc-finger transcription factor that binds to a WGATAR site in the 5Ј-flanking region of target genes and is highly expressed as early as e15 in the primordial genital ridge (88); and Sox9, an Sry-related homeobox gene that, when mutated, causes campomelic dysplasia and can cause sex reversal (89 -91) . A 180-bp proximal promoter region was found to be sufficient to drive expression of mouse MIS in 15-d postnatal Sertoli cells (92) , and in that region an SF-1 binding site (93) was required for activation, since a 2-bp mutation abrogated expression. GATA-4 could activate MIS transcription and does so synergistically when coexpressed with SF-1 (88, 94, 95) . Mutation of a Sox9 binding site provided convincing evidence that it too was critical for MIS expression both in vitro (96) and in vivo (97) . Complicating this interpretation is the observation that, in both chickens (98) and alligators (46), Sox9 expression follows MIS expression temporally. Since MIS is expressed in both male and female embryonic gonads in chickens and an increase in MIS expression in males is coincident with an increase in Sox9 expression (98) , these observations may indicate a mechanism for Sox9-mediated up-regulation of MIS expression above basal levels.
We discovered (99), using adenoviral transfection of 2-d postnatal rat Sertoli cells, which on matrigel continued to express MIS for 6 d in culture (100) , that multiple combinational interactions were required to maintain MIS expression. By contrast, when postnatal bovine Sertoli cells were cultured on plastic, MIS production fell dramatically and could not be sustained (101) . We found that within the Ϫ269 region of the human promoter, that proximal and distal SF-1 sites and proximal and distal GATA-4 sites, as well as a Sox9 site, were required for activation of MIS, as measured by luciferase expression. In addition to these functional transcription assays, EMSAs and deoxyribonuclease I footprinting confirmed the importance of these combinatorial sites (99) . Strict requirements for a functional Sox9 were further confirmed by "knocking in" mutations at the Sox9 site, which caused the phenotype in the male of retention of the Mü llerian ducts, whereas an inserted mutation of the proximal SF-1 site diminished, but did not ablate, MIS expression (97) . Given the latter observation in this in vivo model, it is anticipated that mutation of both SF-1 sites would likely produce complete inactivation, since double mutation of the proximal and distal SF-1 sites ablated luciferase activity in vitro in transfection reporter assays in postnatal day 2 Sertoli cells, when compared with the single mutations alone (99) . The essential Sox9 site, located between the distal and proximal SF-1 sites, and the GATA-4 binding sites may permit DNA bending and binding to enhance the activation of the MIS promoter (99). While not directly binding to DNA, Dax-1 (dosage-sensitive sex reversal, adrenal hypoplasia congenital, critical region on the X chromosome gene-1) (102, 103) , which is mutated in congenital adrenal hypoplasia (104) , acts as a repressor of this combinatorial activation by recruiting the nuclear corepressor, NCoR (105) , whereas the Wilms' tumor suppressor, WT1, acts as an enhancer (106) of MIS activation. These observations raise the intriguing possibility that inhibiting an inhibitor of MIS expression might be useful should higher MIS concentrations prove therapeutic.
Intuitively, one would expect that the inverse correlation between postnatal MIS expression and serum T (Fig. 2 ) was due to either androgen regulation of MIS expression or the regulation of the T homeostasis by MIS, or both. There is evidence for both activities, and regulation of the steroidogenic pathway in Leydig cells by MIS is discussed later in Section IV.A. Analyses of patients with either central or gonadotropin-independent precocious puberty and androgen insensitivity syndromes supported the hypothesis that elevated levels of serum T were concomitant with lower levels of MIS and that the result of ablation of AR signaling was elevated serum MIS (62, 66). The serum of normal mice injected daily for 5 d after birth with PMSG showed a significant reduction in MIS concentration, whereas AR mutant Tfm mice and normal mice injected with PMSG and FSH, respectively, showed the opposite effect (107). These results suggest that the LH component of PMSG could lower MIS expression by stimulating T synthesis.
When LH or T was injected directly into fetuses on day 18 -19 of gestation, holo-MIS immunostaining remained the same, but specific immunostaining for the C-terminal or the N-terminal fragment on day 21 increased (108) . From these results we speculated that T stimulated the enzyme responsible for cleavage of MIS. When fetuses were injected similarly with FSH, immunostaining for MIS was reduced using all three antibodies, indicating that FSH inhibits MIS synthesis, in support of previous observations using antisera to GnRH (77). No cAMP-responsive elements are evident in the MIS promoter, suggesting that the effect is probably not a direct transcriptional one. A synergy between entry of primary spermatocytes into the meiotic prophase and androgen down-regulation of MIS expression has also been observed in mice (107, 109) , which may also be the case in humans even though down-regulation of MIS expression can occur in the absence of spermatogenesis, as is found in patients with germ cell depletion (63). An alternative explanation for the inverse correlation between meiosis and MIS concentration is that higher levels of MIS inhibit completion of the first meiotic division, which has been shown in immature rat ovaries (110) . The increased expression of MIS that correlated with the death of germ cells in ectopic gonads (79) leaves open the search for a germ cell inhibitor of MIS expression.
It has been one of our early goals, as yet unattained, to restore MIS expression in aging ovaries in the hope of averting postmenopausal ovarian cancer. However, turning on regulation of MIS is an intricate combinatorial mechanism that has so far been elusive and labyrinthine.
F. MIS transgenics and knockouts
Overexpression of human MIS in mice resulted in the expected phenotype of females with blunt vaginas and lacking Fallopian tubes and uteri (111) , providing in vivo confirmation that, in otherwise normal mice, expression of the MIS gene was sufficient for Mü llerian duct regression. Interestingly, the chronic exposure of these females to MIS under control of the metallothionein promoter led to other reproductive tract anomalies, such as loss of germ cells in the ovaries and their reorganization into seminiferous tubulelike structures in the adult. When this "freemartin" effect was also produced after ectopic transplantation of fetal gonads and correlated with the loss of germ cells, MIS immunostaining in the induced tubules increased, indicating that the germ cells suppressed MIS expression (79). Subsequent studies showed that folliculogenesis, aromatase activity, and meiosis were retarded by MIS in the ovaries (112) . Males expressing the highest levels of MIS were also abnormal. They were undervirilized externally, had impaired Wolffian duct development, and had undescended testes, all presumably due to Leydig cell hypoplasia (111) , which was later shown to be due to the effect of MIS overexpression on Leydig cell development and steroidogenic capacity (113) .
In addition to the identification of mutations in MIS (114) or its receptor (115) in patients with persistent Mü llerian duct syndrome (PMDS), the function of MIS and the specificity of the MIS type II receptor (MISRII) were unequivocally established when separate knockouts of the ligand (116) and receptor (117) produced identical phenotypes of viable male offspring with retention of the Mü llerian ducts. Older males were noted to have Leydig cell hyperplasia and the rare Leydig cell tumor. Double knockouts of inhibin and MIS had a higher incidence of Leydig cell neoplasias that were seen earlier, were less hemorrhagic, and produced less E2 than the testes of inhibin-deficient controls (118) . These findings prompted studies in a number of laboratories of the role of MIS in the regulation of Leydig cell development and T expression, which will be discussed below (see Section IV.A). The specificity of the MISRII for the MIS ligand was demonstrated by producing combined MISRII-null and MISoverexpressing females that were normal despite very high levels of MIS (119) .
III. MIS Receptor
Determining the molecular mechanisms involved in MIS signal transduction has essentially paralleled that of the TGF␤ family paradigm. Although the mechanisms of many other members of the family, notably TGF␤, activin, bone morphogenetic proteins (BMPs), and growth and differentiation factors (GDFs), have been well characterized (Fig. 3) , progress with MIS has been slower. However, the discovery of a mutation in MISRII in a patient with PMDS (115) and deletion of the MISRII gene by homologous recombination in mice (117) provide conclusive evidence of its identity.
A. Signal transduction in the TGF␤ family
Signal transduction by members of the TGF␤ family of glycoprotein homodimers occurs by a well conserved sequence of events that are initiated by ligand binding to a heteromeric complex of single-transmembrane, serine/threonine kinases resulting in the type I receptor being phosphorylated by the type II receptor (120) . The 55-60 kDa type I receptors (also known as activin receptor-like kinases, ALKs) and the higher molecular weight type II receptors are so called because of their migration distances by PAGE after cross-linking with iodinated ligand (121, 122) .
The signal transduction pathways employed by the TGF␤ family have fallen into two distinct sets: the TGF␤/activin group of type I receptors (ALK5, -1, and ALK4) and the BMP/GDF group (ALK1, -2, -3, and -6). The ligand specificity within the family is determined by the type II receptor, which binds ligand cooperatively with the type I receptor in the case of BMP/GDF or else recruits the appropriate type I receptor into the complex as with TGF␤/activin. The ligand-bound type II receptor phosphorylates the type I receptor, activating its latent kinase for subsequent downstream signaling via intracellular Smad proteins that usually translocate to the nucleus to affect gene transcription (123) . It has also been observed that all of the type I receptors interact with the immunophilin, FKBP12, which could function to block the activation of its latent kinase activity until the GS domain is phosphorylated by the ligand-bound type II receptor kinase (124, 125) .
Smads fall into three different classes, receptor-regulated R-Smads, inhibitory Smads, and the common Smad4 (123).
The R-Smads2 and -3 are phosphorylated by the TGF␤/ activin type I receptors ALK4 and -5, whereas the R-Smads1, -5, and -8 are phosphorylated by the BMP/GDF type I receptors ALK2, -3, and -6. These phosphorylated Smads then dimerize with the common Smad4 to form heteromeric complexes that translocate to the nucleus and effect their respective activities by binding to the Smad-responsive DNA element CAGAC, alone with a relatively loose specificity or in a supercomplex with cofactors that can modulate ligandspecific gene expression (120) such as forkhead activin signal transducer (FAST-1) and the cAMP responsive elementbinding protein (CREB)-binding protein (CBP)/p300 (126 -129) .
B. MIS type II receptor (MISRII)
The MISRII cDNA was first isolated from a rat Sertoli library by a differential hybridization screen for T-regulated genes but was subsequently found to be unregulated by T (130) . Genomic and cDNA clones were also isolated from rabbit fetal ovaries (131), human postnatal testes (115) , rat urogenital ridges (132) , and mouse (133) and human fetal testes (134) . The gene for the human MISRII was localized to 12q12-q13 and contains 11 exons spanning approximately 8 kb, far smaller than other type II receptors in the TGF␤ family (115, 135) . However, the predicted amino acid sequence of MISRII indicates that it is a characteristic type II receptor, which shares 30% overall homology with other TGF␤ family type II receptors.
The mRNA corresponding to MISRII was localized to the Mü llerian duct by in situ hybridization at the time when the Mü llerian duct is undergoing regression and to fetal Sertoli cells and granulosa cells of both embryonic and adult gonads. Sertoli cells in males and granulosa cells in females surround the germ cells and produce MIS; expression of both ligand and receptor in the same cell suggests an autocrine activity in the fetal male gonad and the postnatal male and female gonad. In the postnatal ovary, expression of MISRII is largely restricted to granulosa cells of preantral and small antral follicles (136) . Similarly, in the postnatal testis, developmental expression of the MISRII mRNA in gonads studied by Northern blot analysis indicates that the receptor is highly expressed embryonically, during Mü llerian duct regression, and postpubertally, with relatively little or no expression perinatally (132) . Expression of MISRII is not uniform in the seminiferous tubules and appears to be lowest at stages XII and highest at stage VII when FSH binding is lowest and MIS expression is highest in these structures (137) . An unexplored, but nonetheless intriguing, finding is that MISRII is also expressed in the postnatal uterus (97, 132) . Expression of MISRII has also been observed in Leydig cells, which respond to MIS by lowering T production both in vitro and in vivo (see Section IV.A).
As in the MISRII knockout mouse, in which the MISRII gene is inactivated by homologous recombination (117), mutations of MISRII were found in patients with PMDS. For example, at the splice donor site of intron 2 (115), a 27-bp deletion in exon 10, the most common mutation found (138, 139) , and a number of other mutations are dispersed throughout the coding region (138, 139 fecundity (117) , it would appear that MIS is not required for either blastocyst implantation or fetal and embryonic development.
Regulation of MISRII expression has been studied in vitro, but to date the only transcription factor shown to be essential for receptor expression is SF-1 (140, 141) . None of the MISRII promoters, rat, mouse, or human, contains canonical TATA or CCAAT boxes, and the rat promoter contains 150-bp inverted Alu-like repeats, the function of which is unclear. The rat MISRII promoter contains two SF-1 sites, each of which could function in the absence of the other site to promote transcription of a luciferase reporter in R2C cells, a rat Leydig cell line that expresses SF-1. Mutation of the proximal, loweraffinity SF-1 site actually enhanced transcription, suggesting that binding of SF-1 to both sites simultaneously might be inhibitory (141) . In a teratocarcinoma cell line, NT2/D1, expression of human MISRII was also dependent on SF-1 binding to its single site in the promoter, and increasing the amount of SF-1 in HeLa cells correlated directly with transcriptional activation of the luciferase reporter (140) .
Homozygous deletion in mice of Wnt-7a, a member of the Wg/wnt family of secreted proteins that determine cell fate and polarity and early pattern formation, resulted in the loss of MISRII expression in the Mü llerian duct (142) . The Wnt7a-deficient mice were infertile because the retained Mü llerian ducts blocked sperm passage in males, and the differentiation of oviducts and uteri was abnormal in females. Wnt proteins signal through the frizzled family of receptors and activate ␤-catenin, which translocates to the nucleus and interacts with lymphoid enhancer factor 1 (LEF 1), to function as a transcription factor (reviewed in Ref. 143 ). The molecular mechanisms of Wnt-7a-regulated expression of MISRII is an area worthy of investigation given the observation that ␤-catenin might be involved in Mü llerian duct regression (22); this suggests that MIS might regulate the expression of its own receptor even though the level of expression of MISRII in both male and female Mü llerian duct mesenchyme appears similar (132) . In MA-10 cells, MIS appears to inhibit the expression of the MISRII mRNA, but not an MISRII promoter/luciferase reporter (J. Teixeira, unpublished data).
C. Candidate MIS type I receptors (MISRIs)
While a number of type I receptors for the TGF␤ family have been cloned, the identity of the specific MISRI has been more difficult to deduce. The localization of ALK2 mRNA (first known as R1 or ActR1A) to the mesenchyme surrounding the embryonic Mü llerian duct (See Fig. 4) at the time of Mü llerian duct regression made it a likely candidate (144) . Recent reports suggest that either ALK6 (145) and/or ALK2 (146, 147) might be involved in MIS signaling, and results with ALK3 conditional knockout mice favor it as the candidate MISRI (S. Jamin and R. Behringer, personal communication). Ligand-dependent coimmunoprecipitation of the MISRII with ALK6, but not ALK2, was observed in cells permanently transfected with MISRII, as was activation of a downstream signaling cascade that induces the expression of a BMP-responsive Xvent2 reporter gene in MISRII-transfected P19 cells (145) . However, antisense oligonucleotides of ALK2 coding sequence, but not ALK6 coding sequence, specifically blocked regression of the Mü llerian duct in organ culture and diminished the activation of the BMP-responsive Tlx-2 reporter gene in P19 cells transfected with MISRII and treated with MIS (146) . Tlx-2 reporter expression was also attenuated by transfection and expression of dominantnegative ALK2, but not ALK6 (146) . Inhibition of Tlx-2 reporter expression by ALK2 was also observed in P19 cells transfected with MISRII using a series of truncated mutants of the type I receptors (147) . Smad6 induction was also observed after addition of MIS to MA-10 cells, which express endogenous MISRII (147) . Colocalization of the ALK2 mRNA with MISRII in the mesenchyme surrounding the Mü llerian duct by in situ hybridization further supported the identity of the MISRI as ALK2 (146, 147) . ALK2 expression in the urogenital ridge, which has a short window of responsiveness to MIS, is sexually dimorphic by in situ hybridization, being highly expressed in the male ridge that is destined for regression but much lower in the female ridge (147) . The diminished expression of ALK2, as well as Smad1 and -8, in the female urogenital ridge may explain why higher concentrations of MIS are required for regression of the agonadal female ridge than that of males in culture (P. K. Donahoe, unpublished data), which we speculate might provide the female fetus with some additional protection against exogenous MIS from a male twin. The strong expression of ALK2 observed in the coelomic epithelium in these studies might also explain why human ovarian cancers, which predominantly originate from the coelomic epithelium, might be targets for MIS (134) .
The ALK6 knockout males (148) did not have retained Mü llerian ducts (147) , and wild-type males expressed ALK6 in the epithelium of the Mü llerian duct but not in the surrounding mesenchyme with the MISRII (147, 149) , indicating that, at least in Mü llerian duct regression, ALK6 is probably not involved or is perhaps redundant. These results suggest the possibility that MIS might employ different type I receptors in different cell types. Since knockout of ALK2 was embryonic lethal, resulting in complete block of mesodermal induction at the gastrulation stage (150), targeted inactivation of ALK2 in the urogenital ridge by a Cre/Lox mechanism probably with the MISRII promoter driving Cre expression, as has been done with ALK3 (S. Jamin and R. Behringer, personal communication), will be needed to prove conclusively that ALK2 is the MIS type I receptor used in Mü llerian duct regression.
All three reports provide evidence that Smad1, -5, and -8, which are known to transduce signals for a number of BMP/ GDF ligands (120) , also transduce the signals from MIS (145) (146) (147) . Smad1 phosphorylation in Sertoli-and Leydig-derived cell lines was observed in response to MIS (145) , and a Smad1/Gal4 DNA binding domain fusion construct can activate a Gal4-responsive promoter in P19 cells with added MIS (147) . Of note was the observation that, in the mesenchyme surrounding the Mü llerian duct, Smad8 expression appears more robust than Smad1, while Smad5 is barely detectable (147) . However, in P19 cells, overexpression of Smad5 was able to induce MIS-mediated activation of an ALK2-responsive luciferase reporter, and overexpression of a mutant Smad5 attenuated that response (146) . Thus, it is likely that the MIS receptor-regulated Smad will be in the BMP/GDF pathway but that the choice of the Smad1, -5, or -8 may be tissue-or cell-specific. It is important to understand the signal transduction pathway for MIS in tissue-, development-, and tumor-specific contexts that could lead to a small molecule screen to uncover possible leading candidates to replace or enhance the ligand as a therapeutic.
IV. MIS in the Adult
The signal activity of MIS is to cause regression of the Mü llerian duct in male embryos, but MIS continues to be produced by the testes into adulthood well after Mü llerian duct regression is completed. Ovaries begin producing MIS before birth at low levels that can be detected by immunohistochemistry but are difficult to detect in serum by ELISA until puberty and throughout adulthood when MIS can be readily measured. One of the greatest challenges in the MIS field has been to appreciate and understand the other roles for MIS. The MIS transgenic and knockout mice have yielded unmistakable clues that led to the discovery of the importance of MIS in steroidogenesis and ovarian function. The cloning of the MISRII has also provided an important tool with which to identify other target tissues for MIS action.
A. MIS in the testis
Expression of MISRII has been detected in Sertoli cells, indicating an autocrine role for MIS, which was first suggested by the inhibition of aromatase activity by MIS in cultured primary Sertoli cells (151) . Inhibition of aromatase activity by MIS had also previously been observed in fetal ovary cultures (152) . MIS is also present in seminal fluid of various species (153) (154) (155) (156) (157) at concentrations that may be significantly higher than that observed in adult serum. Normal adult human males had a mean seminal fluid concentration of MIS of 150 pm vs. 11 pm in serum, and higher seminal fluid concentrations of MIS were associated with hypospermatogenesis in patients with nonobstructive azoospermia (157) . Although MISRII expression is not observed in round spermatids (130), MIS can be detected bound to sperm by immunohistochemistry with MIS-specific antibodies where it might be involved in sperm motility (155, 158) .
The paracrine effects of MIS on Leydig cell development and function are better understood. Except for a short period after birth in human males (see Fig. 2 ), there is a reciprocal relationship between the concentration of serum MIS and T such that when MIS is at its highest, T is at its lowest and when MIS falls at puberty, T rises. After puberty, the expression of MIS is greatly reduced in males to the low levels observed in females (48, 59, 60, 62). The low level of T observed in childhood correlates with the paucity of remaining fetal Leydig cells after birth when this population of cells appears to die off. Another population of Leydig cells differentiates from mesenchymal precursors to progenitor Leydig cells before puberty, then to immature Leydig cells, and finally to adult Leydig cells at puberty. These mature Leydig cells are the source of T in the adult (159) .
A paracrine role for MIS had been postulated for Leydig cell differentiation and function because of the phenotypes observed in mice that were manipulated to either overexpress MIS or lacked functional MIS or its receptor. Male mice chronically overexpressing MIS had lower levels of T (112) and Leydig cell hypoplasia: in those mice expressing the highest levels of MIS, undervirilized external genitalia were observed (111) . Conversely, mice with null mutations in either MIS or MISRII had Leydig cell hyperplasia and other gonadal abnormalities (116, 117) .
Subsequent analyses showed that normal Leydig cells express MISRII by RT-PCR (113) and that differentiation of the Leydig cells in the MIS-overexpressing mice was blocked, leading to a decrease in both immature and mature Leydig cell number. Steroidogenic function was also repressed with decreased testicular mRNAs for the T biosynthetic pathway enzymes, cytochrome P450, cholesterol side-chain cleavage (P450SCC), 3␤-hydroxysteroid dehydrogenase/⌬ 5 -⌬ 4 -isomerase (3␤HSD), and most significantly, cytochrome P450C 17-20 hydroxylase/lyase (Cyp17), which catalyzes the committed step in T synthesis (113) . In contrast, as one might expect, analysis of Cyp17 in MIS-deficient mice was higher than normal (113) . Incubation of primary Sertoli cell and Leydig cell cultures with MIS showed a dramatic effect on aromatase activity and T secretion, respectively (151) . Using a combination of Northern blot analyses and flow cytometry with highly purified populations of developmental stagespecific Leydig cells, MISRII expression was shown in both progenitor and immature cells, but MIS binding was only observed with progenitor cells, suggesting that MIS might be involved in the differentiation of the progenitor to immature Leydig cells (160) . MIS was found to inhibit T synthesis by 10-fold when added to MA-10 cells, a mouse Leydig cell line, and to do so, in part, at the transcriptional level of Cyp17 (161) . A single ip injection of MIS in mice was shown to lower serum and testicular T by 9-fold and Cyp17 mRNA by 2-fold after 24 h (162) . Despite dramatic reduction in T concentration, there was little affect on 17-hydroxyprogesterone concentration, which supported that MIS might also be regulating the lyase activity of Cyp17, but not its hydroxylase activity, at least in the mouse. It is tempting to speculate that MIS might play a role in controlling androgen production in syndromes such as precocious puberty or may be an adjuvant to suppress T synthesis for benign prostatic hypertrophy, prostate cancer, and polycystic ovarian syndrome.
B. MIS in the ovary
Although MIS is difficult to detect in the serum of normal females before puberty, MIS expression in the ovaries has been observed as early as 32 wk gestation in humans (63). In rodents, MIS expression in the ovary has been detected by postnatal day 3 (163, 164) . MISRII has also been detected in theca cells or maturing follicles by in situ hybridization (165) . The theca cells in the ovary are the T-producing counterpart of the Leydig cells in females. Expression of MISRII in those cells suggests that MIS might also regulate the steroidogenic capacity of theca cells to produce T as it does with Leydig cells. Although homozygous deletion of the gene for either MIS ligand or its type II receptor in mice resulted in overtly normal females (116, 117) , subsequent analyses showed that the MIS-null mice had more advanced follicle recruitment for age than wild-type mice, resulting in an earlier depletion of the primordial follicles (166) . Heterozygous mice had an intermediate number of follicles, suggesting that follicle recruitment is inversely proportional to MIS concentration. Complicating this interpretation are the results shown with follicles isolated from 12-d-old rats, which indicate that addition of MIS induces preantral follicle growth in culture (167) . Since primordial follicles do not appear to express MISRII (136), a secondary effect of MIS has been proposed. These results may be explained by the observation that MIS inhibits both aromatase activity and LH receptor number in FSH-stimulated granulosa cells of postnatal rats and pigs, respectively (168) .
Earlier studies have shown that MIS inhibits the first meiotic division of diplotene oocytes in immature rats (110) , but this has not been confirmed by others (169) . In addition, MIS blocked epidermal growth factor-induced steroidogenesis, and proliferation of human granulosa-luteal cells in vitro (170) and the concentration of MIS in follicular fluid were inversely proportional to mitotic indices of granulosa cells in vivo (171) . Thus, MIS appears to have an autocrine, as well as an endocrine, role in maturation of normal follicles.
V. Alternative MIS Signal Transduction
Although it is clear that MIS, like other members of the TGF␤ family, signals through the Smad pathway originally found to be used in BMP downstream signaling, there is recent evidence of MIS-mediated downstream effects involving the cell cycle (172) and the nuclear factor-B (NFB) pathway (173) , as well as the ␤-catenin/lymphoid enhancer factor pathway (22). Antiproliferative activities of MIS in normal ovarian and ovarian cancer cell lines, for example, correlated with changes in cyclin-dependent kinase (CDK)/ cyclin, and in normal breast and breast cancer cell lines, required activation of NFB. As with other pathways, including cAMP (174) , MIS signaling might not occur in a cell in a simple linear progression through Smads. It is likely that interaction with other intracellular pathways such as Ras or Jak/Stat might occur to create a complex combinatorial matrix of signaling networks that may or may not involve the entire MISRII/RI receptor complex. While the candidate MISRI has not been investigated in these settings, studies of the effect of MIS on ovarian and breast cancers indicate that they at least express the MISRII.
A. MIS-mediated signal transduction in the ovary
In addition to its well established role in the regression of the Mü llerian duct in male embryos, MIS has been shown also to inhibit the proliferation of several transformed human cell lines in vitro, including human epithelial ovarian cancer cells and a cell line derived from the normal ovarian surface epithelium, the origin of human epithelial ovarian cancers (51, 134, 172, [175] [176] [177] and other tumors of Mü llerian duct origin, as well as ocular melanomas in vivo (51, 52, 54, 178) . Although early studies with rhMIS were only minimally effective against a series of gynecological tumor cell lines in vitro (179) , later studies of its efficacy with highly purified recombinant material (172) or rhMIS produced ectopically (180) have been more convincing. Since female mice that overproduce MIS demonstrate ablation of the ovary, a role for MIS in the postnatal development of the ovary can be inferred. Using Northern and Western blot analyses, MISRII has been detected (172) in both ovarian cancer cell lines and in HOSE6 -3 (human ovarian surface epithelium), an immortalized cell line derived from laser dissection of the coelomic epithelium covering the normal ovary (181) .
MIS-mediated inhibition of ovarian cancer cell proliferation correlated with interference with cell cycle progression and induction of apoptosis (172) . Cell cultures treated with MIS demonstrated a 10 -15% increase in the G 1 phase fraction compared with untreated cells. Cell cycle progression through the G 1 phase of the cell cycle is regulated through a complex mechanism that involves the phosphorylation of the retinoblastoma (Rb) family of pocket proteins. The members of this family (Rb, p107, and p130) are phosphorylated by the cyclin/CDK complexes, the kinase activity of which is negatively regulated by the CDK inhibitors (CDKI). In vitro inhibition of proliferation by MIS of the human ovarian cancer cell line, OVCAR 8, and of the immortalized ovarian surface epithelium cell line, HOSE 6 -3, correlated with upregulation of the CDKI p16 protein (172), a member of the INK4a family of CDKIs, which specifically inhibit the kinase activity of cdk4 and cdk6. Up-regulation of p16 protein expression correlated with increased protein stability and possibly enhanced translation, since p16 mRNA expression remained unchanged. Up-regulation of p16 is necessary for MIS-mediated growth inhibition since expression of antisense p16, which impedes p16 translation, blocks MIS effects on ovarian cancer cells. In addition to atrial natriuretic peptide, which inhibits cell cycle progression in astrocytes through stimulation of p16 mRNA (182) , MIS is the only other peptide hormone known to induce the expression of p16. Precedent is further provided by the fact that growth inhibition by TGF␤, activin, BMP2, and BMP4 can be mediated through induction of the CDKIs, p15, p21, and p27 in many cells lines (183) (184) (185) (186) . The ability of MIS to increase p16 expression selectively indicates that TGF␤ family members inhibit cell proliferation using distinct molecular pathways.
The most well known mechanism by which CDKIs interfere with cell cycle progression is by preventing the phosphorylation of the Rb family of proteins, which includes Rb, p107, and p130 (187) . The lack of Rb protein expression in OVCAR 8 and HOSE 6 -3 cells suggests that MIS-mediated inhibition of ovarian epithelial cell proliferation occurs through an Rb-independent pathway, possibly by employing another protein of the Rb family. In support of this latter mechanism, we found that MIS treatment selectively suppressed expression of the p130 protein in OVCAR-8 cells after 4 d of MIS treatment, but did not suppress expression of p107. The delay required to observe p130 suppression reflects an indirect mechanism that may involve decreased transcription, translation, or the stability of the p130 protein.
The decrease in p130 protein expression in MIS-treated ovarian cancer cells correlated with an increase in E2F1, a transcriptional regulator that, in addition to facilitating cell cycle progression into the S phase, is a potent inducer of apoptosis. E2F1 null mice develop many tumors, including tumors of the ovary and uterine horn (188) , tissues that are known to express high levels of MISRII mRNA (132) .
Overexpression of p16 can regulate apoptosis in many cell types. Whereas induction of p16 protein is an early event, the apoptosis observed after treatment of OVCAR 8 with MIS is delayed and probably indirect. Delayed induction of apoptosis after overexpression of p16, p18, and p27 has been demonstrated in A549, HeLa, SKOV-3, and MTA1A2 cells (189) . Apoptosis of OVCAR-8 cells may result from the induction of E2F1, the growth-inhibitory effect of which is inhibited by Rb family proteins. Expression of p16 is low or absent in one-third of primary epithelial ovarian cancers due to homozygous deletions, missense mutations, or hypermethylation of the promoter (190 -193) . Thus, up-regulation of p16 protein by either gene transfer techniques or MIS treatment could offer therapeutic benefit in the treatment of ovarian cancer patients.
B. MIS-mediated signal transduction in the breast
While the MIS-overexpressing mice indicate that the ovary and ovarian cancer might be targets for MIS, knockouts and overexpressing mice give no clear evidence for the breast as a target. MISRII expression, however, was demonstrated in recent studies in normal breast, breast fibroadenomas and adenocarcinomas, and breast cancer cell lines using several different techniques, suggesting that the breast might be a potential target for the action of MIS (173) . In addition to blocking the growth of ovarian cancer cells, MIS also inhibited the growth of both ER-positive and -negative human breast cancer cells in vitro. As with inhibition of ovarian cancer cell proliferation, MIS-mediated inhibition of breast cancer cell proliferation resulted from an increase in the fraction of cells in the G 1 phase of the cell cycle and induction of apoptosis as measured by increased levels of caspase-3 activity and annexin V staining. MIS treatment of breast cancer cell lines induced the DNA binding activity of the NFB family of transcription factors (173) initially shown to play a key role in mediating inflammatory responses. Abrogation of MIS-induced growth inhibition of breast cancer cells by expression of the dominant negative IB␣ demonstrates that activated NFB is required for this process.
A role for NFB activation in breast epithelial cell growth and differentiation is becoming increasingly evident. 1) NFB DNA binding activity is strongly induced during postlactational involution (194) , a period of extensive apoptosis in the breast. 2) NFB p50/p65 heterodimers inhibit ␤-casein expression by interfering with phosphorylation of STAT 5 (195) . 3) NFkB DNA binding activity and expression of transactivators and inhibitors of NFkB are misregulated in primary breast cancer and cancer cell lines (196 -198) .
MIS selectively up-regulated IEX-1S, the short form of IEX-1, via an NFB-dependent pathway both in vitro (173) and in vivo (199) . Overexpression of IEX-1S inhibited growth, suggesting that it might be a putative suppressor of breast cancer cell proliferation (173) . Testing the effects of MIS on the growth of ER-positive and -negative mammary carcinoma cell growth in vivo will be important to determine whether MIS would be of potential therapeutic benefit in the treatment of breast cancer, thereby expanding the potential tumor targets of MIS as a therapeutic.
The majority of mammary gland growth and differentiation occurs in the adult animal during puberty and pregnancy. We have found that MISRII expression varies inversely with breast growth. Treatment of adult virginal female mice with MIS results in increased apoptosis of mammary duct epithelium (199) , suggesting MIS may play a significant physiological role in controlling involution of the normal breast.
VI. Outlook for MIS
A. Genetics of MIS and MIS receptor in persistent Mü llerian duct syndrome
Seminal studies were done by analyzing families with PMDS, predicting that since homozygous deletion of either the MIS or the MISRII gene resulted in male mice with retained Mü llerian ducts (116), a cadre of patients would have abnormalities in the MIS ligand or the MISRII. This prediction was demonstrated in a series of papers (114, 139, 200, 201) , the last of which studied the molecular genetics of PMDS in 69 families (Fig. 5 ). Mutations were almost equally divided between the ligand and the receptor. The fact that patients with the retained Mü llerian duct phenotype may have gene abnormalities either in the MIS ligand or the MISRII proves that they are in the same pathway. Most of the mutations were located in the N-terminal domain of MIS, which resulted in low or absent levels of MIS in the serum, which can be detected by ELISA. Patients lacking MIS by ELISA are further screened by single-stranded conformational polymorphism of the GC-rich MIS gene to detect the mutated region. After the MISRII was identified, a mutation in the 5-splice donor site for intron 2 was found that led to aberrant splicing of the gene product in mRNA prepared from a biopsy of testicular tissue in a patient with PMDS (115) . The receptor gene is now first studied by PCR for a defect in exon 10 of the receptor because analysis of 69 families of patients with PMDS indicated that a 27-bp deletion in exon 10 was the most common defect observed in patients with a mutated receptor (139) . Sequencing is necessary to detect other defects that can span the entire 8 kb of the MISRII gene.
B. Genetics of MIS receptor in ovarian and breast cancer
Most human ovarian cancers are cystadenocarcinomas (134) , which histologically are similar to the Mü llerian ductderived Fallopian tube, making ovarian cancer a logical target tumor for MIS and justifying the continued efforts to purify the MIS protein and to understand all the elements of its downstream pathway. It is of interest that the incidence of ovarian and breast cancers increases dramatically after menopause, at a time when the normal ovary no longer produces MIS. These tumors also occur in a smaller but significant population of younger patients with a marked familial propensity. It is these young women with familial ovarian and breast cancer in whom we are studying MISRII using the paradigm established for patients with PMDS (139) . Should this receptor be normal, we will continue to search for abnormalities in genes uncovered in the MIS pathway, such as p16, or genes regulated by MIS, such as E2F1.
Similar analyses of MISRII and IEX-1S may prove useful in young patients with breast cancer.
C. New delivery systems
When one searches for a potential anticancer therapeutic it is important that the net be spread broadly. In the case of MIS, one can focus on the efficacious MIS ligand, which we have purified to homogeneity and are now producing for extensive preclinical testing. The downstream molecular pathway found in the course of eliciting apoptosis in these target tissues is also being studied systematically. Knowledge of this pathway will give clues to potential small molecules that can be developed to modulate the pathway. These therapeutics could potentially be more useful than MIS itself if engineered to be orally active. Equally important is the continued search for target genes that are activated or inhibited by treatment of target cells with MIS. An intense study of the transcription factors that regulate those genes, as well as the transcription factors that activate the expression of MIS, is justified since they may conceivably be substituted for or used synergistically with the ligand. Knowledge of the complete pathway raises the possibility of discovering molecules that can superactivate the pathway. The ideal candidate would be a nontoxic small molecule, which can be made to usurp the pathway in a cell-or tumorspecific manner.
If, however, the therapeutic must be the complex ligand, which has the advantage of receptor specificity, then delivery systems take on increased importance. We have employed the principles of tissue engineering using a biodegradable mesh as a scaffold for the creation of neoorgans (202) made from cells transfected with the MIS gene for continuous production of the MIS protein in vivo. This strategy bypasses the need for pharmaceutical scaleup and production of complex molecules, which, at present, fail to make it into the ratelimiting "incubator queue."
As a proof of principle we have transfected CHO cells with genomic MIS and confirmed that they produce and secrete MIS into the media, where MIS can be quantified by ELISA. After the cells are seeded onto a biodegradable mesh, MIS secretion is first confirmed in vitro, after which the mesh is implanted into immunosuppressed mice. Increasing levels of MIS production can be detected in the serum of the animals. When human ovarian tumors were implanted beneath the renal capsule of these animals, growth of the tumor was significantly suppressed (180) . It is the ultimate goal of these experiments to seed a patient's own cells onto the mesh after in vitro transfection of the cells with the MIS gene. It will be interesting to determine whether an implanted MIS-producing neoorgan can achieve sufficiently high levels to suppress tumor growth in vivo in humans, as was observed in immunosuppressed mice (180) . If continuous production is found to down-regulate receptor-mediated effects, then systems employing induction constructs may need to be engineered.
D. Other sources of MIS
If one is to use MIS for therapeutic purposes, an inexpensive and reliable source must be found. To achieve this, we are investigating the production of MIS in plants. A novel promoter strategy based on the plant's response to pressure or touch has been developed and is being employed to express rhMIS in tobacco plants. Since MIS is a glycoprotein, concern whether plant glycosylation will produce a product that is immunogenic in humans, led us to produce only the bioactive nonglycosylated C-terminal domain of the MIS gene. We can now detect secreted C-terminal human MIS from transfected plants by Western blotting and have observed bioactivity in the Mü llerian duct regression assay (K. Oishi, D. T. MacLaughlin, and P. K. Donahoe, unpublished data). Production of MIS is being scaled up and will be tested in a number of other functional assays for MIS bioactivity.
VII. Conclusion
Thus, the study of MIS, an important molecule in normal sex differentiation and reproductive function, has revealed unexpected actions and pathways such as the regulation of androgen synthesis, where it may prove to be an important tool in uncoupling the lyase and hydroxylase activities of Cyp17 and serve as an adjunct in therapies of androgen excess syndromes. Dissection of its growth-inhibitory activities has revealed new targets for MIS, such as breast and ovarian cancers, cell lines of which have provided systems in which to explore systematically tissue-specific signal transduction pathways activated by MIS. Steps in these pathways may reveal therapeutics or adjuvants for the treatment of these cancers. The careful genetic analysis of patients with the rare form of male pseudohermaphroditism, PMDS, provides strategies that can be employed in patients with early or familial ovarian or breast cancer. Because of the precisely timed expression of both the MIS ligand and the MISRII during spermatogenesis and follicular recruitment, we speculate that MIS function is important in the dialogue between germ cells and Sertoli/granulosa cells resulting in precise control of germ cell maturation in both the ovary and testes. Another area worthy of study is the elucidation of second signals from the mesenchyme surrounding the Mü llerian duct where the MISRI and MISRII colocalized, to the epithelium, which responds by breakdown of the basement membrane surrounding the Mü llerian duct epithelial cells followed by apoptosis or migration of the epithelial cells. Out of a series of unleashed proteolytic enzymes or other molecules may fall molecular signals that will be intriguing to explore. The other activities of MIS do not require the paracrine mesenchymal interactions that are required for Mü llerian duct regression, and it will be interesting to compare these direct and indirect mechanisms.
Paralleled with efforts to scale up and deliver the MIS ligand, these studies will reveal new functions, targets, downstream pathways, and genes regulated by MIS or regulating MIS and its receptors, any one of which could serve as a therapeutic or function as an adjuvant with MIS in the treatment of diseases in which the MIS pathway plays an important physiological or pathophysiological role. The additional dividend of potential clinical benefit gives an even stronger imperative to the continued study of MIS, which has revealed the importance of this molecule in normal development and differentiation and elucidated pathways important for a fuller understanding of the activities of the larger TGF␤ family and how specificity is achieved through complex combinatorial rearrangements of common pathway molecules. 
